MedDataX Logo

Arterial Stiffness in Individuals With Breast Cancer

NCT ID: NCT07070778

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-08

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate vascular toxicity induced by anthracyclines and other anticancer drugs and to measure arterial stiffness in women with breast cancer and, in addition, to evaluate the acute and chronic arterial stiffness responses of upper extremity aerobic exercise training.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer is the most common type of cancer in women both in the world and in our country. Today, with the technological developments, breast cancer treatments have improved considerably and the mortality rate has decreased. However, despite the developments in treatments, the quality of life of patients has still not reached the desired level. Upper extremity dysfunctions are frequently observed in patients after breast cancer treatment. This upper extremity dysfunction causes a decrease in the quality of daily life of patients. Arterial stiffness contributes to hypertension and increases the risk of cardiovascular disease. The American College of Sports Medicine (ACSM) recommends that healthy adults perform moderate to vigorous intensity aerobic exercise at least 5 times per week and resistance exercise 2-3 times per week. Aerobic exercise can reduce arterial stiffness after both acute and chronic interventions. A small number of studies on aerobic exercise have reported that this exercise training improves the functional level of patients after breast cancer. However, the effect of aerobic exercise training on arm exercise capacity and arterial stiffness in patients with breast cancer is still unclear. Thus, the results of this study may guide physiotherapists working in this field about upper extremity exercise training after breast cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aerobic Exercise Breast Cancer Arterial Stiffness

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

breast cancer Aerobic exercise training Arterial Stiffness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The study consists of one group: this group performs upper extremity aerobic exercise training.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Upper Extremity Aerobic Exercise

Participants will only receive a 12-week upper extremity aerobic exercise training program.

Group Type OTHER

Upper Extremity Aerobic Exercise Training Program

Intervention Type OTHER

12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Upper Extremity Aerobic Exercise Training Program

12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be between the ages of 40-69,
* Baseline left ventricular ejection fraction (LVEF) \>50%,
* Absence of coronary artery disease and haemodynamically significant valvular heart disease,
* Absence of carotid atherosclerotic plaques,
* Volunteering to participate in the research,
* At least 15 months after breast cancer surgery,
* No problems in reading and/or understanding the scales and being able to co-operate with the tests.
* Physically inactive (60 minutes of structured exercise per week \<).

Exclusion Criteria

* Presence of active infection,
* Presence of bilateral breast cancer,
* History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery,
* Having a neurological disease or other clinical diagnosis that may affect cognitive status,
* Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy
* Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease.
* Presence of unstable hypertension or diabetes mellitus.
Minimum Eligible Age

40 Years

Maximum Eligible Age

69 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hacettepe University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ebru Calik Kutukcu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Melda Saglam, PhD

Role: STUDY_CHAIR

Hacettepe University

Ebru Calik Kutukcu, PhD

Role: STUDY_DIRECTOR

Hacettepe University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hacettepe University

Ankara, State, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ebru Calik Kutukcu, PhD

Role: CONTACT

Phone: +903123051576

Email: [email protected]

Naciye Vardar-Yagli, PhD

Role: CONTACT

Phone: +03123051576

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ebru Calik Kutukcu, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025/5-39

Identifier Type: -

Identifier Source: org_study_id